The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Ab Initio Biotherapeutics; Forty Seven
Leadership - Ab Initio Biotherapeutics
Stock and Other Ownership Interests - Ab Initio Biotherapeutics; Forty Seven
Consulting or Advisory Role - Ligand
Patents, Royalties, Other Intellectual Property - Patent US10316094B2, owned by Stanford University and licensed to Forty Seven, Inc.; Patent US9562087B2, owned by Stanford University and licensed to Ab Initio Biotherapeutics, Inc. (now owned by Ligand Pharmaceuticals); Patent US9845345B2, owned by Ab Initio Biotherapeutics, Inc. (now Ligand Pharmaceuticals).
Travel, Accommodations, Expenses - Forty Seven
 
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Co-inventor on technologies that have been licensed to Forty Seven Inc
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
 
David Andrew Sallman
Consulting or Advisory Role - Agios; argenx; Celyad
Speakers' Bureau - Abbvie; Agios; Celgene; Incyte; Novartis
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Intellectual Property Patent for LB-100 in MDS
 
Monzr Al Malki
No Relationships to Disclose
 
Adam Steven Asch
Research Funding - Astellas Pharma (Inst); Cartesian Therapeutics (Inst); Forty Seven (Inst); Juno Therapeutics (Inst); Macrogenics (Inst); MEI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent submitted (I)
 
Daniel Junseung Lee
Consulting or Advisory Role - Boston Biomedical
Research Funding - Abbvie/Genentech (Inst); Bayer (Inst); Forty Seven (Inst); Tolero Pharmaceuticals (Inst)
 
Suman Kambhampati
No Relationships to Disclose
 
William Bruce Donnellan
Consulting or Advisory Role - Abbvie; Seagen
Research Funding - Incyte; Kite/Gilead; Novartis; Pfizer; PTC Therapeutics; Seagen
 
Terrence James Bradley
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Novartis; Novartis
 
Paresh Vyas
Stock and Other Ownership Interests - OxStem
Honoraria - Abbvie; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Pfizer
Research Funding - Celgene; Forty Seven
Patents, Royalties, Other Intellectual Property - Patent for flow cytometric detection of leukaemic stem cells
 
Deepa Jeyakumar
No Relationships to Disclose
 
Guido Marcucci
Honoraria - Abbvie; Novartis
Speakers' Bureau - Abbvie; Novartis
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - agios; Celgene; Daiichi Sankyo; incyte; Janssen; Novartis; Pfizer
Speakers' Bureau - Alexion Pharmaceuticals; Jazz Pharmaceuticals; Novartis
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Daiichi Sankyo; Incyte; Jazz Pharmaceuticals; Novartis
 
Joanna Van Elk
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Research Funding - Forty Seven
Travel, Accommodations, Expenses - Forty Seven
 
Ming Lin
Employment - Forty Seven; Gilead Sciences
Stock and Other Ownership Interests - Forty Seven; Gilead Sciences
 
Roy Maute
No Relationships to Disclose
 
Jens-Peter Volkmer
No Relationships to Disclose
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Consulting or Advisory Role - Biomotiv
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Hepatx
Honoraria - D2G Oncology
Consulting or Advisory Role - Chimera Bioengineering
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Naval Guastad Daver
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Immunogen; Incyte; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Nohla Therapeutics; Pfizer; Servier